Volume 62, Pages S47-S52 (December 2002)

Slides:



Advertisements
Similar presentations
Volume 54, Pages S135-S139 (December 1998)
Advertisements

Volume 78, Issue 8, Pages (October 2010)
Volume 56, Pages S238-S241 (July 1999)
Volume 62, Issue 2, Pages (August 2002)
Robert C. Stanton, MD  American Journal of Kidney Diseases 
Iron status and iron supplementation in peritoneal dialysis patients
Epidemiology of diabetic nephropathy in Spain
Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation  Anil K. Bidani, M.D., Karen A. Griffin,
Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani 
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes  Robert W. Schrier, Raymond.
Glomerulus number and blood pressure in the Prague hypertensive rat
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function  Susan E. Shoaf, Patricia Bricmont, Suresh.
Volume 63, Pages S88-S90 (June 2003)
Volume 88, Issue 2, Pages (August 2015)
Need for better diabetes treatment for improved renal outcome
Is there a pharmacologic basis for combination renin axis blockade?
Volume 69, Pages S11-S15 (April 2006)
Volume 70, Pages S21-S25 (December 2006)
Volume 90, Issue 3, Pages (September 2016)
Volume 57, Pages S32-S37 (April 2000)
Volume 56, Issue 4, Pages (October 1999)
Robert C. Stanton, MD  American Journal of Kidney Diseases 
How to interpret the eGFR in patients with small body surface area
Volume 74, Issue 3, Pages (August 2008)
A new era in phosphate binder therapy: What are the options?
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.
Volume 73, Pages S5-S17 (April 2008)
Volume 72, Issue 12, Pages (December 2007)
Recent experience with high-dose intravenous iron administration
Volume 68, Issue 2, Pages (August 2005)
SYMPLICITY: not all that simple
Volume 82, Issue 7, Pages (October 2012)
Volume 63, Pages S38-S42 (February 2003)
Proteinuria and hypertensive nephrosclerosis in African Americans
Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia 
Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes  J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.
The kidney, a cardiovascular risk marker, and a new target for therapy
Counteracting progression of renal disease: A look into the future
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Measurement of renal function in pre-ESRD patients
Volume 54, Pages S135-S139 (December 1998)
Volume 73, Issue 8, Pages (April 2008)
Volume 58, Issue 3, Pages (September 2000)
Volume 58, Issue 5, Pages (November 2000)
Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita  Kidney International 
Volume 67, Pages S15-S19 (January 2005)
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study1  Robert N. Foley, Charles A. Herzog, Allan J.
The course of the remnant kidney model in mice
Volume 62, Issue 2, Pages (August 2002)
This Month in AJKD American Journal of Kidney Diseases
Volume 68, Issue 5, Pages (November 2005)
Volume 60, Issue 3, Pages (September 2001)
Volume 56, Pages S238-S241 (July 1999)
Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension  Julian Segura, Carlos Campo, Luis M. Ruilope  Kidney.
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Volume 68, Pages S98-S102 (December 2005)
Charles A. Herzog  Kidney International 
Volume 75, Issue 1, Pages (January 2009)
Volume 62, Pages S36-S41 (December 2002)
Molecular and structural consequences of early renal allograft injury
Renal replacement therapy in Latin America
Evaluation of the Losartan in Hemodialysis (ELHE) Study
Renal vascular disease in the elderly
Volume 73, Issue 11, Pages (June 2008)
Kidney and hypertension
Volume 54, Pages S112-S119 (December 1998)
Antonio Piccoli, Luana Pillon  Kidney International 
Presentation transcript:

Volume 62, Pages S47-S52 (December 2002) Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies  José Luño, Vicente Barrio, Maria Ángeles Goicoechea, Cesar González, Soledad García De Vinuesa, Francisco Gómez, Carmen Bernis, Mario Espinosa, Francisco Ahijado, José Gómez, Pedro Escalada  Kidney International  Volume 62, Pages S47-S52 (December 2002) DOI: 10.1046/j.1523-1755.62.s82.10.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Percentage of patients who achieved the maximum, medium and minimum dose of medication in each study group. Symbols are: (▪) maximum; () medium; (□) minimum. Kidney International 2002 62, S47-S52DOI: (10.1046/j.1523-1755.62.s82.10.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Changes in creatinine clearance (CCr) by treatment groups throughout the study period. Symbols are: (solid line) candesartan; (dashed line) lisinopril; (dotted line) combination of candesartan and lisinopril therapy. There were not significant changes between groups at any time. Kidney International 2002 62, S47-S52DOI: (10.1046/j.1523-1755.62.s82.10.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 Mean ± SD serum potassium (mmol/L) by treatment groups during the study period.*P = 0.036 comparing mean serum potassium in the lisinopril group at 3 months with baseline data. **P = 0.042 comparing mean serum potassium in the combination therapy group at 3 months with baseline data. Symbols are: (□) baseline data; () two months; () 3 months; (▪) 6 months. Kidney International 2002 62, S47-S52DOI: (10.1046/j.1523-1755.62.s82.10.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 4 Blood pressure changes (mm Hg) by treatment groups throughout the study period.P < 0.005 from first month until end of follow-up for both systolic and diastolic compared to baseline, P was non-significant between groups at any time point. Symbols are: (solid line) candesartan; (dashed line) lisinopril; (dotted line) combination of candesartan and lisinopril therapy. Kidney International 2002 62, S47-S52DOI: (10.1046/j.1523-1755.62.s82.10.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 5 Mean ± SE of urinary protein/creatinine ratio (g/g) by treament groups during study period two, three and six months comparing with baseline. Symbols are: (□) baseline data; () two months; () three months; (▪) six months. Kidney International 2002 62, S47-S52DOI: (10.1046/j.1523-1755.62.s82.10.x) Copyright © 2002 International Society of Nephrology Terms and Conditions